3 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 8 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Terminated 3, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
Follow Recurrent Waldenstrom Macroglobulinemia: new trials by email Literature Review of Recurrent Waldenstrom Macroglobulinemia trials Research Report on Recurrent Waldenstrom Macroglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 38 | 2026-09-30 | 2026-10-05 |
| Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia Ibrutinib, Ixazomib Citrate, Laboratory Biomarker Analysis - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 2 | Terminated | Mayo Clinic | 21 | 2018-08-14 | 2026-05-05 |
| Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma Carfilzomib, Laboratory Biomarker Analysis, Rituximab - Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 2 | Terminated | University of Washington | 4 | 2017-12-18 | 2020-01-18 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 150 | 2017-09-11 | 2026-05-14 |
| Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Selinexor - Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Barbara Ann Karmanos Cancer Institute | 43 | 2017-06-20 | 2026-10-23 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2011-07-20 | 2021-10-04 |
Waldenstrom Macroglobulinemia (8) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (4) · Lymphoma, Mantle-Cell (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Burkitt Lymphoma (1) · Hematologic Diseases (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic (1)
Blood Protein Disorders (8) · Cardiovascular Diseases (8) · Hemic and Lymphatic Diseases (8) · Hemorrhagic Disorders (8) · Hemostatic Disorders (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Plasma Cell (8) · Paraproteinemias (8) · Vascular Diseases (8) · Hematologic Diseases (7)
CT-P10 (2) · Rituximab (2) · Sirolimus (2) · ibrutinib (2) · Biopsy (1) · Bortezomib (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Cyclosporine (1) · Cyclosporins (1) · Dexamethasone (1) · Lenalidomide (1) · Magnetic Resonance Spectroscopy (1) · Mycophenolic Acid (1) · Nivolumab (1)
Mayo Clinic (3) · Barbara Ann Karmanos Cancer Institute (1) · David Bond, MD (1) · Fred Hutchinson Cancer Center (1) · National Cancer Institute (NCI) (1) · University of Washington (1)
United States (8)
Asher A. Chanan-Khan, M.D. (1) · David Bond, MD (1) · Dipenkumar Modi, M.D. (1) · Leonard T Heffner (1) · Masumi Ueda Oshima (1) · Prashant Kapoor, MD (1) · Stephen Smith (1) · Wei Ding (1)
PMID 28424162, PMID 33785483, PMID 41043099
P30CA015704 (2), P01CA078902 (1), P30CA022453 (1), P50CA097274 (1), U10CA021115 (1), U10CA180820 (1)